Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05369052
Other study ID # MRXC-302
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 3, 2022
Est. completion date June 2024

Study information

Verified date May 2023
Source MicuRx
Contact Clinical coordinator
Phone 510-782-2022
Email info@micurx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.


Description:

Approximately 865 subjects (519 contezolid acefosamil/contezolid: 346 linezolid) will be enrolled with moderate or severe DFI that are confirmed or suspected to be due to a Gram-positive bacterial pathogen (MITT analysis set).


Recruitment information / eligibility

Status Recruiting
Enrollment 865
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have diabetes mellitus (type 1 or 2) per the American Diabetes Association criteria - Have a foot infection that started at or below the malleolus and does not extend above the knee - Foot infection that meets the IWGDF DFI criteria for classification 3 (moderate infection) or 4 (severe infection) - Foot infection had acute onset or worsening of signs and symptoms within the past 14 days Exclusion Criteria: - Previous DFI known or suspected to be caused by Gram-positive pathogens that are resistant to oxazolidinone antibiotics - DFI with presumptive evidence or suspicion of osteomyelitis - Necrotizing fasciitis, crepitant cellulitis, wet gangrene, gas gangrene, ecthyma gangrenosum, septic arthritis, or severely impaired arterial supply to any portion of the affected foot which may need revascularization before the end of the study - Evidence of significant hepatic, renal, hematologic, or immunologic disease - Females who are pregnant or breastfeeding - Prior receipt of any formulation of contezolid acefosamil or contezolid - Inability to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be noncompliant with any study requirements, or the Investigator determines that the subject should not participate in the study

Study Design


Intervention

Drug:
contezolid acefosamil (IV)/contezolid (PO)
Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Linezolid (IV and PO)
Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)

Locations

Country Name City State
Bulgaria MHAT Blagoevgrad AD, Department of Surgery Blagoevgrad
Bulgaria UMHAT - Sveti Georgi EAD Plovdiv
Bulgaria Multiprofile Hospital for Active Treatment - KANEV Ruse
Bulgaria Medical Institute Ministry of Interior Central Clinical Base Sofia
Bulgaria UMHAT - Sofiamed Sofia
Bulgaria UMHAT - Prof. Stoyan Kirkovich Stara Zagora
China West China Hospital Chengdu Sichuan
China Chongqing No. 4 People's Hospital Chongqing Sichuan
China The Second Affiliated Hospital of Chongqing Medical University Chongqing Sichuan
China Hainan Medical College No. 2 Affiliated Hospital Haikou Hainan
China Affiliated Hospital of Yunnan University Kunming Yunnan
China Zhongda Hospital Southeast University Nanjing Jiangsu
China The Second Affiliated Hospital of Guangxi Medical University Nanning Guangxi
China The Second Affiliated Hospital of Shantou University Medical Center Shantou Guangdong
China The First Hospital of Hebei Medical University Shijiazhuang Hebei
China Chu Hsien-I Memorial Hospital of Tianjin Medical University Tianjing Tianjin
China The Central Hospital of Wuhan Wuhan Hubei
China Union Hospital Tongji Medical College Huazhong University Wuhan Hubei
China Xi'an Medical University First Affiliated Hospital Xi'an Shaanxi
China Affiliated Hospital of Jiangsu University Zhenjiang Jiangsu
Estonia Ida-Viru Central Hospital Kohtla-Järve
Estonia Tartu University Hospital Tartu
Estonia Viljandi Hospital Viljandi
Estonia South-Estonian Hospital Ltd. Võru
Greece General Hospital of Athens-Laiko Athens
Italy AORN - Ospedali dei Colli - Ospedale D. Contugno Napoli
Latvia Daugavpils Regional Hospital Daugavpils
Latvia Riga East Clinical University Hospital Riga
Lithuania Hospital of Lithuanian University of Health Sciences Kaunas
Lithuania Vilnius University Hospital Santaros Klimkos Vilnius
Portugal Hospital de CUF Descobertas Lisboa Lisboa
Puerto Rico Clinical Research Management Group, Inc. Mayagüez
Spain Hospital del Mar Barcelona
United States Billings Clinic Research Billings Montana
United States Velocity Clinical Research Chula Vista California
United States New Hope Research Development Corona California
United States Sacramento VA Medical Center Mather California
United States University Medical and Research Center, LLC Miami Florida
United States Floridian Clinical Research, LLC Miami Lakes Florida
United States Perseverance Research Center. LLC Scottsdale Arizona
United States South Jersey Infectious Disease Somers Point New Jersey
United States Harbor-UCLA Medical Center Torrance California

Sponsors (1)

Lead Sponsor Collaborator
MicuRx

Countries where clinical trial is conducted

United States,  Bulgaria,  China,  Estonia,  Greece,  Italy,  Latvia,  Lithuania,  Portugal,  Puerto Rico,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators The primary objective is to evaluate the Investigator's assessment of clinical response at the D35 visit in subjects receiving contezolid acefosamil/contezolid compared to subjects receiving linezolid in the MITT analysis Day 35
Primary Adverse events - symptoms reported by subjects Evaluate safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) 28-35 days after End-of-Therapy (EOT)
Primary Clinical laboratory assessment - complete blood count Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) 28-35 days after End-of-Therapy (EOT)
Primary Vital signs - heart rate Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) 28-35 days after End-of-Therapy (EOT)
Secondary Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators Evaluate the Investigator's assessment of clinical response at EOT visit in the MITT analysis set 14-28 days
Secondary Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators Evaluate the Investigator's assessment of clinical response at Day 10 (D10) and Late Follow-Up visits (LFU; 28-35 days after EOT) in the MITT analysis set Day 10, 28-35 days after EOT
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05613985 - PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers N/A
Recruiting NCT03964571 - Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients N/A
Completed NCT03230175 - Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01) Phase 2
Completed NCT05616351 - Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
Recruiting NCT05948592 - Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection Phase 2
Recruiting NCT04714411 - Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Completed NCT05243810 - EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers N/A
Recruiting NCT05610865 - Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Phase 1
Recruiting NCT04450693 - Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) Phase 3
Completed NCT02723539 - A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI Phase 1
Completed NCT04440839 - Implementation of Telemedicine for Patient With Lower Extremity Wounds N/A
Withdrawn NCT04289948 - Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes Phase 1/Phase 2
Completed NCT03495349 - Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Completed NCT05564728 - Diabetes Footcare Companion App for Patients and Carers
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Completed NCT01590758 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Completed NCT01594762 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Active, not recruiting NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients Phase 2
Recruiting NCT04141787 - Ceftriaxone as Home IV for Staph Infections Phase 4